SCHEMBL155167

SCHEMBL155167

CCc1ccc(CN2CCCCC2)cc1

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.78
HRH4 Q9H3N8 1/20 0.69
ALDH1A1 P00352 5/20 0.67
KDM4E B2RXH2 3/20 0.67
POLB P06746 2/20 0.66
MEN1 O00255 1/20 0.65
GFER P55789 1/20 0.65
KMT2A Q03164 1/20 0.65
CYP2D6 P10635 1/20 0.62
CYP2C19 P33261 1/20 0.62
TSHR P16473 1/20 0.61
NCF1 P14598 1/20 0.60
MBTD1 Q05BQ5 1/20 0.59
L3MBTL3 Q96JM7 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7406183 0.98 HRH3 (0.75) HRH3HRH4ALDH1A1KDM4EPOLB
SCHEMBL8244456 0.98 HRH3 (0.74) HRH3HRH4ALDH1A1KDM4EPOLB
SCHEMBL4277270 0.89 HRH3 (1.00) HRH3HRH4ALDH1A1KDM4EPOLB
SCHEMBL3040325 0.88 HRH3 (0.70) HRH3HRH4POLBCYP2D6CYP2C19
Hydrochloric Acid SCHEMBL7468055 0.86 HRH3 (0.95) HRH3HRH4ALDH1A1KDM4EPOLB
SCHEMBL11201497 0.86 HRH3 (0.94) HRH3HRH4ALDH1A1KDM4EPOLB
Hydrochloric Acid SCHEMBL11196296 0.84 HRH3 (0.90) HRH3HRH4ALDH1A1KDM4EPOLB
SCHEMBL13062773 0.83 HRH3 (0.72) HRH3HRH4ALDH1A1KDM4EPOLB
SCHEMBL19671018 0.83 CHKA (0.77) ALDH1A1KDM4EPOLBNCF1
SCHEMBL329323 0.83 HRH3 (0.78) HRH3HRH4ALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372297-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2023-11-23 US disclosed
US-20230174933-A1 METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS NOVARTIS AG (CH) 2023-06-08 US disclosed
US-11584805-B2 Oligosaccharide compositions and methods for producing thereof DSM NUTRITIONAL PRODUCTS, LLC (US) 2023-02-21 US disclosed
US-20220251152-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION NOVARTIS AG (CH) 2022-08-11 US disclosed
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-10-14 US disclosed
US-20210002387-A1 OLIGOSACCHARIDE COMPOSITIONS AND METHODS FOR PRODUCING THEREOF HERCULES CAPITAL, INC. 2021-01-07 US disclosed
US-20190307159-A1 OLIGOSACCHARIDE COMPOSITIONS FOR USE AS FOOD INGREDIENTS AND METHODS OF PRODUCING THEREOF HERCULES CAPITAL, INC. 2019-10-10 US disclosed
US-10329257-B2 Compositions and methods for treating tuberculosis THE BROAD INSTITUTE, INC. (US) 2019-06-25 US disclosed
US-20190038600-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES BOEHRINGER INGELHEIM INT (DE) 2019-02-07 US disclosed
EP-2258356-B1 CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES CT INGENIERIA GENETICA BIOTECNOLOGIA (CU) 2017-09-27 EP disclosed
WO-2009158587-A1 METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS INSPIRE PHARMACEUTICALS, INC. (US) 2009-12-30 WO disclosed
WO-2009155209-A1 OPHTHALMIC FORMULATION OF RHO KINASE INHIBITOR COMPOUND INSPIRE PHARMACEUTICALS, INC. (US) 2009-12-23 WO disclosed
WO-2008145681-A2 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-04 WO disclosed
WO-2008077057-A2 CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE INSPIRE PHARMACEUTICALS, INC. (US) 2008-06-26 WO disclosed
US-7384952-B2 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-10 US disclosed
US-7384952-B2 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-10 US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329257-B2 Compositions and methods for treating tuberculosis C5, IFNG, TERT HRH3 2194/4885HRH4 1456/4885ALDH1A1 1848/4885
US-20210002387-A1 OLIGOSACCHARIDE COMPOSITIONS AND METHODS FOR PRODUCING THEREOF OSTC, FUT5, FUT6 HRH3 3895/4885HRH4 3871/4885ALDH1A1 2641/4885
US-11584805-B2 Oligosaccharide compositions and methods for producing thereof OSTC, FUT5, FUT6 HRH3 3895/4885HRH4 3871/4885ALDH1A1 2641/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 HRH3 303/4885HRH4 120/4885ALDH1A1 2458/4885
US-20230372297-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES MMP1, COL1A1, SMAD3 HRH3 380/4885HRH4 368/4885ALDH1A1 174/4885
US-20190038600-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES MMP1, COL1A1, IDO1 HRH3 335/4885HRH4 253/4885ALDH1A1 200/4885
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE MELK, HIPK1, HIPK3 HRH3 2877/4885HRH4 3749/4885ALDH1A1 3459/4885
US-20230174933-A1 METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS HAVCR2, MICA, CD74 HRH3 2526/4885HRH4 3991/4885ALDH1A1 3289/4885
US-20220251152-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION RPS27A, PSMG3, PREP HRH3 3656/4885HRH4 3890/4885ALDH1A1 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.